Celiac disease products

Celiac disease affects 1% of the population and therefore is the most common chronic inflammation of the small intestine triggered by cereal gluten/gliadin uptake in genetically susceptible individuals. The gluten induced autoimmune disorder is characterized by autoantibodies to tissue transglutaminase (TG2), antibodies to deamidated gliadin and villous atrophy in the final stage.

TG2 plays a central role in celiac disease. Besides being the major autoantigen it is involved in the pathogenesis. Under certain circumstances and in distinct environments as given in the inflamed gut TG2 catalyzes deamidation of glutamine side chains in gliadin yielding glutamic acid. Deamidated gliadin is subsequently recognized by receptors of the immune system triggering celiac disease.

Related gluten induced autoimmune disorders are dermatitis herpetiformis / Morbus Duhring (autoantigen: epidermal transglutaminase, TG3) and neurological disorders like gluten ataxia (autoantigen: neuronal transglutaminase, TG6).

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland